Dupixent (Dupilumab) Denied: How to Appeal Atopic Dermatitis, Asthma, and COPD Denials

Dupixent (dupilumab) is a biologic that targets the IL-4/IL-13 pathway and is FDA-approved for moderate-to-severe atopic dermatitis (eczema), moderate-to-severe asthma with eosinophilic phenotype or oral corticosteroid-dependent asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, and COPD with eosinophilic inflammation. It is one of the most prescribed biologics in dermatology and allergology — and one of the most frequently denied.

Common Denial Reasons for Dupixent

Step therapy requirements for atopic dermatitis. Insurers routinely require documented failure of at least one or two topical therapies (potent corticosteroids, tacrolimus, pimecrolimus) and often systemic immunosuppressants (cyclosporine, methotrexate, azathioprine, mycophenolate) before approving Dupixent. If your clinical notes don't explicitly state these trials and their outcomes, the Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization will be denied.

Severity criteria. The FDA indication for atopic dermatitis specifies "moderate-to-severe" disease. Insurers may deny if documentation uses vague language rather than validated scoring tools. The IGA (Investigator's Global Assessment) scale, EASI score, or BSA (body surface area) involvement are used to quantify disease severity. If your records don't include these, the insurer may claim severity criteria are unmet.

Asthma eosinophil count requirement. For the asthma indication, many insurers require a blood eosinophil count ≥ 300 cells/μL (or ≥ 150 for oral corticosteroid-dependent asthma). If your eosinophil count falls below the insurer's threshold — or if the count was not included in the prior authorization request — the denial follows automatically.

COPD indication denials. The FDA approved Dupixent for COPD with eosinophilic inflammation in 2024. This is a newer indication and many insurer coverage policies have not been fully updated. Denials frequently occur simply because the plan's coverage criteria predate this approval.

Off-label food allergy use. Dupixent is being used by allergists for peanut allergy, other food allergies, and urticaria. These uses are not yet FDA-approved and will face formulary or medical necessity denials that require extensive clinical documentation and literature support.

How to Build Your Dupixent Appeal

Document prior treatment failure precisely. For atopic dermatitis, provide the specific drugs tried, concentrations used (e.g., triamcinolone 0.1% twice daily), duration of treatment, and the reason for failure — whether inadequate control, side effects (skin atrophy, HPA axis suppression), or contraindication to systemic agents.

Use validated severity scoring. Ask your dermatologist to include EASI, SCORAD, IGA, or BSA percentage involvement in the appeal letter. An IGA score of 3 or 4 clearly documents moderate-to-severe disease. Without objective scoring, the appeal is vulnerable to an insurer claiming severity was not established.

Submit the eosinophil count for asthma. For asthma or COPD appeals, include the most recent CBC with differential showing the absolute eosinophil count. If the count was taken during a course of oral steroids, note that steroids suppress eosinophil counts and the baseline count should be obtained off-steroids.

Invoke step therapy bypass. If your prescriber believes systemic immunosuppressants like cyclosporine are contraindicated (hepatotoxicity, nephrotoxicity, hypertension risk, drug interactions), document this explicitly. Most state step therapy laws allow bypass when required drugs are clinically contraindicated.

Cite quality of life impact. Atopic dermatitis studies consistently show itch scores, sleep disruption, and depression rates comparable to other chronic diseases. Including validated patient-reported outcomes like DLQI (Dermatology Life Quality Index) strengthens medical necessity arguments.

The COPD Pathway

If your Dupixent was denied for COPD, confirm with your prescriber that your records document:

• Confirmed COPD diagnosis (spirometry with post-bronchodilator FEV1/FVC < 0.70)
• Blood eosinophil count ≥ 300 cells/μL
• History of COPD exacerbations despite optimized inhaler therapy
• Type 2 inflammatory phenotype consistent with eosinophilic COPD

Appeal letters citing the BOREAS and NOTUS trial data showing exacerbation reduction in eosinophilic COPD patients significantly strengthen the medical necessity argument.

Fight Back With ClaimBack

Whether your Dupixent denial is for eczema, asthma, COPD, or another condition, ClaimBack helps you translate your clinical situation into the specific language and documentation your insurer requires to approve the drug.

Start your Dupixent appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied